Understand the source comparison
PE-22-28 Compare to Other Research Peptides: Direct Class Comparison
When evaluating how PE-22-28 compare to other research peptides, the first filter is mechanism class. Peptides fall into distinct categories: GLP-1/GIP receptor agonists (semaglutide, tirzepatide), growth hormone secretagogues (GHRP-2, ipamorelin), mitochondri
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- When evaluating how PE-22-28 compare to other research peptides, the first filter is mechanism class. Peptides fall into distinct categories: GLP-1/GIP receptor agonists (semaglutide, tirzepatide), growth hormone secretagogues (GHRP-2, ipamorelin), mitochondrial modulators (MOTS-C, humanin), and melanocortin agonists (PE-22-28, melanotan II derivatives). Each class operates through entirely separate pathways with minimal mechanistic overlap.
- GLP-1 receptor agonists like semaglutide work by binding GLP-1 receptors on pancreatic beta cells and in the gut, slowing gastric emptying and extending the post-meal satiety window. Half-life ranges from 7 days (semaglutide) to 5 days (tirzepatide). Appetite suppression is dose-dependent and scales with receptor occupancy. Higher doses produce stronger gastric delay. PE-22-28, by contrast, doesn't affect gastric motility at all. Its appetite suppression comes from melanocortin receptor activation in the brain, which shifts the homeostatic set point for energy balance rather than mechanically slowing digestion.
- Growth hormone secretagogues like GHRP-2 and MK-677 stimulate pituitary GH release by binding ghrelin receptors. This produces systemic elevations in IGF-1, which drives anabolic processes. Protein synthesis, lipolysis, nitrogen retention. These peptides don't suppress appetite; many researchers report increased hunger as a side effect because ghrelin itself is an orexigenic hormone. PE-22-28 has no ghrelin receptor activity and no direct growth hormone effect. It's purely a melanocortin-mediated appetite and thermogenesis modulator.
- Mitochondrial peptides like MOTS-C improve insulin sensitivity and metabolic flexibility by enhancing mitochondrial function at the cellular level. MOTS-C activates AMPK pathways that shift metabolism from glucose dependence to fat oxidation. This improves endurance and recovery but doesn't directly suppress appetite or increase thermogenesis the way melanocortin activation does. Researchers examining metabolic health versus appetite regulation need mechanistically different tools. MOTS-C for the former, PE-22-28 for the latter.